Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive ...

Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive ...

2020 has been quite a roller coaster ride for the stock markets. The recent positive developments regarding two COVID-19 vaccine candidates has been a drag on the work-from-home stocks but bodes well ...

Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...

DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic today and set a price target of $105.00. O’Brien covers the Healthcare sector, focusing on stocks such as Medtronic, Dexcom, ...

I last covered DexCom (NASDAQ:DXCM) over 1 year ago, when the company's stock price had collapsed from a then all-time peak of $290 to $191, during the market selloff in response to the onset of the ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...

There's a simple, straightforward argument for investing in Dexcom (DXCM 2.41%). The company specializes in the development of continuous glucose monitoring (CGM) systems, which help diabetes patients ...

This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April. DexCom ...